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AbstrACt
Objectives To explore relevant Finnish stakeholders’ 
perceptions on the automatic substitution of biological 
medicines with particular focus on medication safety and 
issues that need to be considered to create an appropriate 
model for automatic biological product substitution.
Design Qualitative interview study.
Methods Data were collected in semistructured 
individual (n=17), pair (n=7) and group (n=8) interviews 
(32 interviews, 62 participants) in 2018. Participants 
represented a wide range of stakeholders involved in 
the pharmacotherapy process: community pharmacists 
(n=8 interviews), authorities (n=7), prescribers (n=7), 
pharmaceutical industry and wholesalers (n=6), patients/
customers (n=2), hospital pharmacists (n=1) and nurses 
(n=1). Inductive content analysis was performed.
results Benefits of automatic substitution were identified 
as cost savings, more patients receiving biological 
treatments and enhanced continuity of treatment. Six 
major risk categories were identified: (1) the patient’s 
medication is interrupted or complicated temporarily 
or permanently, (2) the patient uses two products with 
the same active substance, (3) the traceability of the 
product is compromised, (4) the patient cannot get into 
healthcare in case of problems, (5) the patient does not 
receive substitution-related advice from a pharmacy and 
(6) the patient is distracted by the support material he/she 
receives. Several risk mitigation measures were commonly 
mentioned: medication and device counselling by 
pharmacists (n=23), infrequent substitution interval (n=15) 
and better knowledge on biosimilars among healthcare 
providers (n=13).
Conclusion Automatic substitution of biologics is 
associated with risks that should be prospectively 
managed before implementing the procedure. The 
substitution also introduces new tasks and communication 
needs to those involved in actual medication use process, 
particularly to community pharmacists who will be 
responsible for substitution and counselling the patients.
IntrODuCtIOn
Biological medicines (‘biologics’), especially 
therapeutic proteins, are used to treat an 
increasing number of patients over a wide 
range of therapeutic indications.1 The high 
costs of original biological medicines repre-
sent a major burden on healthcare budgets.2 
The biosimilar concept with abbreviated 
approval pathway was developed in the Euro-
pean Union (EU) to increase competition 
within biologics’ market.3 Subsequently, 
biosimilars have triggered price competi-
tion and price reductions in several coun-
tries.4 In Finland, hospitals have generally 
adopted biosimilars into their formularies 
mainly through their tendering processes.4 5 
However, in ambulatory care, the uptake of 
biosimilars has been poor.6 In ambulatory 
care, the decision to switch between biologics 
is made by the prescriber and the incentives 
to switch from a biologic reference product 
to a biosimilar are weak: the social insurance 
reimbursement system covers the majority of 
expenses for the patient either way.5
The introduction of automatic generic 
substitution was an effective way to restrict the 
increase of medication expenditures when 
uptake of generic prescribing lagged.7–10 
From a regulatory perspective, the approaches 
to demonstrate equivalence of generic small 
strengths and limitations of this study
 ► This is the first study to explore potential medication 
safety risks while implementing automatic substitu-
tion of biologics.
 ► Interviews are an effective method to gain an in-
depth understanding of important issues when 
considering a model for automatic substitution of 
biologics.
 ► A wide range of stakeholders participated in the in-
terviews offering their viewpoints.
 ► This study explored varying stakeholder views on 
automatic substitution of biologics rather than com-
pared differences between the stakeholder groups.
 ► The limited number of patients and nurses in the in-
terviews may have influenced the results.
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molecule drugs and biosimilars are analogous; however, 
the requirements to demonstrate the similarity are more 
extensive for biosimilars.11 This is due to the heteroge-
neity of the molecules produced by biotechnological 
processes.12 Theoretical considerations and clinical 
switching studies suggest that biosimilars developed 
according to the EU guidance are interchangeable with 
their reference products.13–20 Furthermore, no consistent 
safety signals from pharmacovigilance reporting systems 
that monitor switching between highly similar biologics 
have been identified.12 21
Several prominent EU regulatory agencies, including 
Finnish Medicines Agency, and medical societies have 
issued position papers supporting the interchange-
ability of biosimilars with their reference products under 
the supervision of the prescriber.22 However, since the 
marketing authorisation process ensures that the biosim-
ilar has the same efficacy and safety profile as the refer-
ence product, relevant changes in treatment are not 
expected on switching.13 Thus, in countries where biosim-
ilars have been regarded as interchangeable, the (auto-
matic) substitution is no longer a scientific question, but 
a political, practical and organisational issue. The aim of 
this study was to explore relevant Finnish stakeholders’ 
perceptions on the automatic substitution of biological 
medicines with the focus on medication safety. In the 
spirit of prospective risk management, our focus was to 
identify issues that should be considered to create an 
appropriate model for automatic substitution of biolog-
ical medicine.
MethODs
Finnish stakeholders’ perceptions on automatic substitu-
tion of biologics were explored by semistructured theme 
interviews. This method is particularly suitable for situa-
tions where it is desirable to elicit a wide range of views on 
a specific topic.23 The theme interview is also well suited 
for previously unstudied topics.24
Interview guide and additional interview material
The flexible interview guide with four themes was devel-
oped (online supplement material 1). The flexibility 
in the guide allowed a conversational and interactive 
approach in the interviews.23 The themes were: (1) atti-
tudes towards automatic substitution, (2) medication 
safety on substitution, (3) prerequisites for implementa-
tion and specific issues pertaining to different perspec-
tives and (4) implementation and monitoring. The 
interview guide was constructed based on the study aim, 
and the research group’s experience and knowledge 
that covered, for example, biosimilar policy making on 
the EU level, implementing the generic substitution at 
the national level as well as extensive medication safety 
research. In the interviews, a table of biosimilars that were 
on the market in Finland in August 2018, and a table of 
biosimilars authorised in the EU, but not launched in 
Finland were made available.
The interview guide was tested in a pilot interview. 
Based on the pilot, the explanations of the key terms 
used in the interview were added to the interview mate-
rial. After this, the guide was adapted but kept open to 
further adjustments during the data collection, partic-
ularly regarding different stakeholder roles. The pilot 
interview was included in the research data.
sampling and recruitment of the interviewees
The study sample covered a full range of national stake-
holders associated with biological medication starting 
from the marketing authorisation to medicine distri-
bution and patient care (online supplement material 
2). The research group identified the stakeholders that 
were invited to participate. Purposive sampling was 
used to select the stakeholders to ensure the coverage 
of all relevant perspectives.25 The following operators 
were included: community and hospital pharmacists, 
prescribers, nurses, patients/customers, pharmaceu-
tical industry, pharmaceutical wholesalers and different 
authorities regarding distribution and pharmacotherapy 
process.
Interviewees were primary recruited through interest 
groups, professional associations and patient organisa-
tions. The aim of the interviews was to obtain rich and 
comprehensive insights from interviewees. The chosen 
organisations were contacted by email. The date and 
time for the interview were agreed by email or telephone. 
The invited organisations independently nominated the 
person or persons to participate in the interview. This 
influenced whether the interview was conducted as an 
individual, pair or group interview. Direct recruits were 
made in situations where it was appropriate (eg, authori-
ties). A total of 38 interview invitations were sent.
Data collection
Written informed consent was obtained from all inter-
viewees. The interviews were audio recorded. The inter-
views were conducted by HMT (female pharmacist, MSc, 
with training in qualitative interviews) in Finnish at places 
that were easily reached by the interviewees and were 
sufficiently private to facilitate a free and confidential 
exchange of information.
At the beginning of each interview, the interviewer 
went through the most important terms (biosimilar, 
substitution and medication safety) used in the interview 
to ensure that the concept would not cause any misunder-
standings. Interviewees were encouraged to share their 
personal views and the possible positions of their back-
ground organisation on the topic.
Data analysis
Audio records were transcribed verbatim by a professional 
transcriber and transcripts were checked for accuracy by 
one researcher (HMT). The identities of the participants 
were anonymized prior to data analysis. Inductive content 
analysis, which is applicable for research topics which are 
not well-known and are expected to yield new insights, 
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Table 1 Number of interviews (n=32) and background of 
the interviewees (n=62)





 ► National and/or local professional 
associations
 ► Practitioners (pharmacy owners, 




 ► Evaluation of interchangeability of 
generics
 ► Pricing





 ► Professional associations
 ► Practitioners from medical specialty 
societies
7 (7)
Pharmaceutical industry and wholesalers
 ► National interest groups




 ► Patient associations
2 (5)
Hospital pharmacists
 ► Hospital drug formulary management
1 (6)
Nurses
 ► Specialist nurse associations
1 (3)
Total 32 (62)
was used.26 27 Data from individual, pair and group inter-
views were analysed in the same way, using the interview 
as the level of the analysis rather than analysing views of 
each individual participants. The data were read through 
several times and sentences relevant to research question 
were coded. Codes that had the same or similar meaning 
were combined. Combined codes were grouped into 
subcategories and further categories that formed, for 
example, perceived risk descriptions that were presented 
in a conceptual model. Suitability of the interchange-
ability for the biologics, as it is recognised in Finland, 
was not in the focus. The data were mainly analysed by 
one researcher (HMT). There were several sessions with 
the research group where data, analysis and preliminary 
results were discussed to improve the trustworthiness of 
the qualitative analysis. The most representative quota-
tions were reported. A checklist of the consolidated 
criteria for reporting qualitative studies was utilised when 
applicable.28
ethical approval
The interviews were conducted in accordance with the 
Finnish National Board of Research Integrity guidelines 
for the ethical principles to conduct a research.29 Ethical 
pre-evaluation was not required, as all interviewees were 
asked for informed consent, only adults participated in 
the interviews and the interviews did not cover the inter-
viewees’ personal health information.
Patient and public involvement
The patients participated in the study as representatives 
of their patient organisations. There was no patient or 
public involvement in the planning phase or design of 
the study. The study participants, including patient repre-




A total of 32 interviews with 62 participants were 
performed between August and November 2018 
(table 1). There were 17 individual interviews. The rest 
were either pair (n=7) or group (n=8) interviews. Each 
pair and group interview included participants only from 
one stakeholder group. The mean duration of the inter-
views was 55 min (range from 30 to 98 min). All interviews 
were conducted face-to-face. In three interviews, there 
were additional participants (n=4) also via Skype or over 
telephone.
Most of the contacted organisations and individuals 
agreed to participate in the study (n=32, 84%). Six 
contacts did not lead to an interview. Three invited stake-
holders refused to participate due to lack of knowledge 
or experience on the topic and two participants dropped 
out since a suitable interview time was not found (group 
interviews). No response was received for one invitation. 
A summary of the characteristics of the participants is 
given in table 1.
General perceptions of biological medicines’ substitution
Practically, all participants in the interviews (n=32) 
preferred physician-led switching as a primary method 
for enhancing the use of biosimilars, whereas varied atti-
tudes regarding automatic substitution of biologics in 
community pharmacies was elicited. In half of the inter-
views (n=16), the position of the attendees was positive 
to the substitution at the pharmacy level. In 25% of the 
interviews (n=8), interviewees suggested that there is not 
enough experience on biosimilars, and they saw risks that 
should be solved prior to initiating automatic substitution 
in pharmacies. Automatic substitution of biologics was 
deemed as a totally inappropriate model in some inter-
views (n=8). Some negative comments reflected distrust 
on quality, safety and efficacy of biosimilars in general. 
Positive and negative attitudes were both found among 
all stakeholders, including patient representatives, and all 
types of interviews (individual, pair or group interviews). 
Treatment-naive patients were perceived to be the most 
suitable for substitution.
benefits of the automatic substitution of biologics
In addition to cost-savings in healthcare (n=17), the 
stakeholders identified several other benefits that might 
copyright.
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Table 2 Potential benefits of substitution at the pharmacy level as identified in the interviews (n=32)
Benefit Description of the benefit Citation from the interview






Lower prices can improve patients’ willingness and 
ability to use self-injectable biological products 
(n=5)
‘… patient’s involvement in the treatment may be better if 
he/she gets a cheaper medicine, it is a bit of problem with 
expensive biological drugs before reaching annual limit for 
co-payment…’ NURSE01
Patients have better access to biological treatments 
(n=5)
‘…lower prices may allow more people to receive 
treatment…’ PATIENT04
Patients may start biological treatment earlier (n=3) ‘… maybe one should not focus only on savings here 
but just how you can treat patients at an earlier stage…’ 
INDUSTRY05
New drug treatments can be introduced without 
compromising sustainability of pharmacotherapy 
(n=2)
‘… with the savings these innovative medicines can be 
offered to more patients…’ PHARMACIST08
Continuity of 
treatments
Treatment can continue smoothly with another 
product if there is a medicine shortage (n=4)
‘… if they were in a kind of generic substitution, there would 
more tools for these disruptions.’ PHARMACIST05
Decreasing prices can increase the pharmacy’s 
willingness to keep the products in stock (n=2)
‘And, of course, depending on which price category the 
product is, if it is always available in the pharmacy as for 
example insulin, as soon as patient gets his medicine, he 
can start using it immediately.’ PHARMACIST01
Patients may receive a 3-month dose of reimbursed 
medication at the same time if the price of the 
product falls sufficiently (n=1)
‘So if that price dropped so much that the customer would 
get it (dispensed medicine) more to take with, and on the 
other hand it would be a good thing for the customer not to 
visit pharmacy every month …’ PHARMACIST14
Treatment can continue smoothly with another 
reimbursed product if there is a change in the 
reimbursement status of the patient’s current 
medicine brand (n=1)
‘But even in this situation (the original product is not 
reimbursed any more) if you speculate that there is a 
drug substitution and you can switch directly to the 
biosimilar, so this recipe ‘exchange rally’ is much smaller.’ 
PHARMACIST01
Automatic substitution could improve immediate 
availability if pharmacies were aware of the product 
that has to be dispensed (n=1)
‘…for example, in this Neupogen case, you should keep 
four different products in stock when you don’t know what 
the doctor prescribes, but with the substitution you only 
need one product to start the treatment…’ AUTHORITY18
be achieved with implementing biologics’ substitution 
(table 2). More patients can receive treatments, if savings 
result in increased number of patients on biological treat-
ment (n=5), initiation of biological treatment in earlier 
phase (n=3) or introduction of novel treatments for new 
patients (n=2). Substantial price reductions may also 
increase patients’ willingness and ability to use biologics 
(n=5), if the price reductions are substantial. Continuity 
of treatment was also identified as a potential benefit, for 
example, in the case of medicine shortages (n=4).
the perceived medication safety risks and their management
Most of the risks with biologics’ substitution identified in 
the interviews were related to the interruption or compli-
cation of patient’s pharmacotherapy because of issues 
such as inadequate knowledge of the administration 
device (n=19), medicine availability problems (n=12) 
or patient’s distrust to the biosimilar medicine itself 
(n=11) (table 3). For example, differences in packages 
and complex naming (n=11) can introduce a risk for 
duplicate therapy. Traceability of the dispensed product 
name and batch number (due to long-term side effects; 
n=8, or unavailability of the dispensed product name or 
batch number; n=5) and insufficient availability of health-
care contacts (n=12) were also identified as medication 
safety risks in substitution in several comments. Lack of 
appropriate training for patients in the pharmacy and the 
inconsistencies between the pharmaceutical product-spe-
cific patient information materials were mentioned as 
risks in some interviews.
Several methods to minimise medication safety risks 
were proposed in the interviews. Medication and device 
counselling provided by pharmacists (n=23), infrequent 
substitution interval (n=15) and better knowledge on 
biosimilars among healthcare providers (n=13) were 
identified as potential remedies in multiple interviews.
substitution frequency
The interviewees were asked about optimal substitution 
interval for biologics. Only three interviewees agreed 
that the current generic substitution interval of 3 months 
(eg, how often the medicine could be substituted in the 
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Table 3 Perceived medication safety risks and their management measures as identified in the interviews (n=32)*
Potential risk Descriptions of perceived risks with manifestation
Methods to minimise risk as identified in the 
interviews (n=32)
The patient’s medication is 
interrupted or complicated 
temporarily or permanently
The patient does not know how or is unable to use the 
administration device correctly (n=19)
 ► The patient feels that the new administration device is 
difficult to use
 ► Patient fails to administer medicine or he/she is not able to 
repeat administration
 ► New administration device is not suitable for the patient 
(handicap, visual impairment)
 ► Too wide a range of different devices is available
 ► Pharmacy provides medication counselling including 
device counselling with optional injection training 
(n=23)
 ► The interval† between substitutions should be longer 
for biological drugs than for generic medicines (n=15)
 ► Further training of healthcare professionals on 
biosimilars (n=13)
 ► Consistent, positive attitude towards substitution 
across healthcare and pharmacies (n=9)
 ► A motivating conversation with the patient by a 
doctor and nurse (n=8)
 ► Ensuring at every pharmacy and healthcare visit that 
the patient can use the device correctly (n=8)
 ► Medication monitoring (n=8)
 ► The patient knows where to contact in case of 
problems (n=7)
 ► Prescriber can prohibit substitution if necessary (n=7)
 ► Evaluation of the interchangeability of devices in a 
regulatory process (n=6)
 ► Dispensing of biologics based on an appointment or 
pre-order (n=6)
 ► Switches and substitution are avoided if medication 
has not been stabilised (n=6)
 ► Evaluation of biological medicines suitable for 
substitution by the regulatory authority (n=6)
 ► Postmarketing surveillance of medicines (n=5)
 ► Regional co-ordination/co-operation between 
healthcare and pharmacies (n=4)
 ► Substitution policy prevents shortages by supporting 
pharmaceutical companies to anticipate the market 
(n=3)
 ► Mandatory reserve supplies of biological medicines 
(n=2)
 ► Providing reliable drug information sources for the 
patient (n=2)
The medicine is not available at the right time (n=12)
 ► The pharmacy does not have the product in stock
 ► There is a medicine shortage
The patient does not trust the new medicine (n=11)
 ► The patient has benefited significantly from the original 
product and does not want to change
 ► The patient receives conflicting messages from different 
healthcare professionals
 ► The substitution will surprise the patient at the pharmacy
 ► Patient is suspicious due to different product appearance 
and trade names
The patient experiences adverse reactions after 
substitution (n=11)
 ► Reactions to excipients
 ► Nocebo-effect
 ► Large-scale substitution may reveal problems that were not 
previously detected
Concern about losing the medicine’s effectiveness (n=8)
 ► The development of drug antibodies is accelerated by 
repetitive switches
 ► There is no large-scale experience on repetitive switches
The patient uses two 
products with the same 
active substance
Based on the appearance or name of the product, it is not 
possible to determine whether the active substance is the 
same (n=11)
 ► Different appearance of packages
 ► Different trade names
 ► Generic names can be confusing
 ► Patient recognises only the established brand name
 ► Demonstrating administration devices in drug 
counselling (visuality) (n=9)
 ► Prescriber can prohibit substitution (n=7)
 ► Printing drug lists and checking medication (n=1)
 ► The new product is marked with a label that indicates 
the substitution (n=1)
 ► The new product is not delivered too early, so the 
patient does not have two products at the same time 
at home (n=1)
 ► Pharmacist invalidates the previous prescription 
when substituting (n=1)
The patient does not understand that substitution has 
taken place (n=8)
 ► Patients with polypharmacy, the elderly, patients with 
impaired cognition
The patient has two prescriptions for the same active 
substance (n=3)
 ► The patient has a prescription for the original product and 
another prescription for the biosimilar
The traceability of the 
product is compromised
The biological drug can have long-term side effects (n=8)
 ► The product that caused a side effect cannot be traced
 ► The interval between substitutions should be longer 
for biologics than for generic medicines (n=15)
 ► Promoting two-way information sharing between 
pharmacy and healthcare services (n=10)
 ► Switches and substitution are avoided if medication 
has not stabilised (n=6)
 ► Introduction of a drug certification system (automatic 
registration of the dispensed package and batch) 
(n=6)
 ► Development of information systems so that the 
batch number of the delivered product is also 
registered in the electronical prescription centre (n=4)
 ► Prescriber can check the brand name of the supplied 
medicine at the electronical prescription centre (n=3)
In case of a side effect, the product cannot be traced (n=5)
 ► The physician is not aware of what brand and what batch 
the patient has used
 ► Patient refers only to the originator’s brand name
Continued
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Potential risk Descriptions of perceived risks with manifestation
Methods to minimise risk as identified in the 
interviews (n=32)
The patient cannot get 
into healthcare in case of 
problems
Healthcare is overloaded due to substitution (n=12)
 ► Substitution increases patient contact with healthcare
 ► Patients with substituted medicine would be in closer 
follow-up. The patient contacts the physician to obtain a 
substitution refusal
 ► Further training of healthcare professionals on 
biosimilars (n=13)
 ► Consistent, positive attitude towards substitution 
across healthcare and various pharmacies (n=9)
 ► A motivating conversation with the patient by a 
doctor and nurse (n=8)
The patient does not 
receive substitution-
related advice from a 
pharmacy
‘On behalf of the patient’ customers (n=5)
 ► For example, a relative can apply for a medicine on behalf 
of a patient
 ► Medication counselling with both visual and written 
material (n=7)
 ► Prescriber can prohibit substitution (n=7)
New methods to dispense medicines (n=1)
 ► The patient can apply for a medicine from the ‘smart box’ 
when convenient
The patient is distracted 
by the support material he 
receives
There may be differences in written material received by 
the patient (n=2)
 ► Material for various products is accumulated
 ► Generic and harmonised risk minimisation materials 
(n=2)
The availability of additional materials may vary by product 
(n=2)
 ► Pharmaceutical company supplies additional product-
specific material such as web pages, storage and shipping 
boxes
*Please note, ‘patient perspective’ can be either patient representative’s view or other stakeholder representative’s assumption on patient’s view.
†In Finland, the substitution interval for generic small molecules (generic substitution interval), eg, how often patient’s medicine could be substituted at the 
pharmacy, is related to the reference price that establish the reimbursement level and is confirmed quarterly (reference price interval) (The Social Insurance 
Institution of Finland. Generic substitution and the reference price system. Available: https://www.kela.fi/web/en/medicine-expenses-generic-substitution-and-the-
reference-price-system(accessed June 2019)).
Table 3 Continued
Table 4 Influence of the substitution frequency on medication safety and attractiveness of the pharmaceutical market in 
Finland emphasised in the stakeholders’ interviews (n=32)
Short substitution interval Long substitution interval
Medication safety Positive impact on
 ► Continuation of treatment in case of shortages 
of a particular product
Negative impact on
 ► Device expertise of the patient
 ► Traceability of the product and batch number
 ► Management of support material for the 
patient
 ► Concerns on immunogenicity
Positive impact on
 ► Device expertise of the patient
 ► Traceability of the product and batch 
number
 ► Management of additional patient 
material
Negative impact on





 ► Predictability of pharmaceutical market
 ► Stock management in pharmacies
Uncertain impact on
 ► Competition between products
Positive impact on
 ► Predictability of pharmaceutical market
 ► Stock management in pharmacies
Negative impact on
 ► Competition between products (prevents 
rapid reaction to price changes)
pharmacy5) would be suitable for biologics and none 
recommended to have an interval of 1 month. The most 
popular interval for substitution was 12–24 months 
(n=13). In some interviews, the participants did not want 
to mention any precise frequency but mentioned that 
it ‘should be done rarely’. Both the validity period of a 
prescription and the adjusted reference price intervals 
for biologics were suggested to determine the interval of 
biologics’ substitution.
Participants suggested an association between substitu-
tion frequency and medication safety and pharmaceutical 
market attractiveness (table 4). It was suggested that a 
long substitution interval may increase medication safety 
compared with shorter intervals. On the contrary, phar-
maceutical companies’ interest to enter local pharma-
ceutical market may be compromised if the substitution 
interval is too long.
tasks and responsibilities of the patients and healthcare 
professionals
Automatic substitution was predicted to bring new tasks 
to community pharmacists (figure 1). Lack of informa-
tion sharing between community pharmacists and nurses 
who are involved in patient counselling was noted in 
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Figure 1 Existing interactions (black lines) between patients and healthcare professionals in biological medicine treatment 
in Finland and new tasks (red boxes) and new interactions (red dashed lines) between patients and healthcare professionals 
induced by automated substitution of biologics identified in the stakeholders’ interviews (n=32).
several interviews. It was highlighted by interviewees that 
this information pathway should be developed for effec-
tive and consistent counselling on administration devices 
for patients. Multiple interviewees stated that collabora-
tion between teams in healthcare and pharmacies should 
be improved before introducing automatic substitution 
of biologics. On the contrary, patients’ role as a partner 
was discussed by the various interviewees.
DIsCussIOn
The stakeholders had a generally positive attitude to 
the biologics’ substitution at the pharmacy level. Treat-
ment-naive patients were regarded as the most suitable 
targets for substitution. The stakeholders identified 
several benefits and risks related to automatic substitution 
of biologics. Many of the risks that were identified in the 
interviews are applicable also to generic substitution, such 
as patients’ expected distrust towards a new medicine and 
a parallel use of the same active ingredients in different 
products (table 3). Traceability of the dispensed product 
name and batch number, and patients’ knowledge and 
training for a new administration device were identified 
as risks that are not shared with generic substitution. 
On the contrary, multiple mitigation measures against 
medication safety hazards were also identified, such as 
infrequent substitution interval, improved knowledge of 
biosimilars among healthcare personnel and administra-
tion device counselling at pharmacies. These measures 
can allocate some new tasks to community pharmacists.
education of healthcare providers and patient counselling
Our study indicates that the personnel in healthcare units 
and community pharmacies need substantial detailed 
information on biosimilars, which is consistent to previous 
findings.30–32 The outcome of automatic substitution may 
be negatively influenced if the provided information is 
ambiguous or not sufficiently detailed.33 The attitudes 
of the prescriber or other providers towards substitution 
have been shown to have an impact on the patient’s accep-
tance to switch medicine and the perceived outcome of 
the switch.34 35 In generic substitution, lack of appropriate 
information has been shown to be confusing and raise 
doubts regarding the quality, safety and efficacy of the 
generic product.36–38
Regarding the experience of generic substitution, it is 
important to provide consistent information to patients 
about biosimilars, the reasons for the switch and the 
product in question. Based on the assessment by the regu-
latory authorities, the marketing authorisation holder 
may be required to produce risk minimisation material, 
such as patient ‘alert cards’ used to manage the adequate 
monitoring of treatment.39 In general, the risk minimisa-
tion material of biosimilars should be consistent with the 
information of the reference product. In order to avoid 
confusion among patients, these materials should be as 
harmonised as possible.39
Our study identified potentially new roles for commu-
nity pharmacists to facilitate safe and effective substitu-
tion of biologics. In Finland, the patient counselling on 
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any biological medicine is usually given by the prescribers 
and nurses. Community pharmacists are obligated by law 
to ensure that the patients know the appropriate use of 
medicinal products, including administration devices.40 
Thus, all suggested new roles are already within the 
current mandate of the Finnish pharmacies. Neverthe-
less, it seems that introducing the substitution of biologics 
would require a major effort to educate and train phar-
macy staff in dealing with biologics and their adminis-
tration devices as well as in patient counselling. General 
information on biosimilars and their interchangeability 
is available in local languages and can be tailored to the 
needs of the pharmacies.41 Ideally, pharmacies and local 
healthcare units should collaborate in developing patient 
counselling materials and techniques in order to increase 
synergy and to avoid overlapping work.
Administration devices
According to our findings, patient’s knowledge of use 
of the administration devices is one of the key factors to 
the success of substitution. The different administration 
devices can present an obstacle to switching.42 However, 
all administration devices for biosimilars and their refer-
ence products have been tested for usability at the time 
of marketing authorisation.43 Still, there may be clin-
ically relevant differences in the usability of different 
devices, as experienced by the patient. Thus, to assure 
safe substitution, the national authority will need to assess 
the suitability of administration devices for substitution 
in all relevant patient groups. For instance, substitution 
may involve the use of a different type of device, such as 
an autoinjector instead of a prefilled syringe. The risk 
for clinically relevant problems when using different 
administration devices can be minimised with adequate 
patient counselling, including device training, and good 
communication within medication management team 
(figure 1). The pharmacy staff should be able to provide 
the necessary device training if the patient or caregiver 
is unfamiliar with the new device in order to ensure the 
appropriate administration of the product.
‘Dispense as written’
According to previous studies, physicians have reserva-
tions regarding automatic substitution.44–49 Some physi-
cians seem to be hesitant to accept automatic substitution 
of biologics because of the perceived limitation of the 
physician’s autonomy.46 50 This was also identified in 
recent Finnish study.51 This view can be challenged, since 
substitution of biosimilars, like generic substitution, 
deals with therapeutically equivalent products. The need 
for automatic substitution is driven by insufficient cost 
consciousness of prescribers who are major players in the 
channelling of public funds.52
Nevertheless, there may be situations in which substi-
tution is not appropriate. According to the local legisla-
tion, the prescribers can prohibit generic substitution by 
writing the prescription with a ‘dispense as written’ desig-
nation.34 53 54 The interviewees in our study suggested that 
this may also be necessary in substitution of biologics. For 
instance, the patient may not have reached an optimal 
treatment response with the present medicinal product. 
In this case, substitution needs to be postponed until a 
rational decision can be made either to substitute or to 
prescribe a product with a different active substance. 
Substitution may also be inappropriate if the patient will 
not be able to use the new product due to physical hand-
icap or other relevant reasons. Nevertheless, the patients 
and healthcare providers may also consider a new device 
as easier to use.55–57 It is important that the physicians will 
have to present a clinically sound justification if they wish 
to prohibit the substitution.
substitution interval
One of the concerns related to substitution was related 
to the frequency of switches. The stakeholders seemed 
to favour longer switching intervals for practical and 
safety reasons. Frequent switching could overload the 
pharmacies in patient counselling and increase the risk 
of medication errors and potential switch-related adverse 
effects, such as nocebo effect. Multiple switches may also 
confuse patients and their caregivers.42 Troubleshooting 
may also be difficult in cases of frequent switching and 
adverse effects with long latency, such as immunogenicity 
and loss of efficacy. A long switching interval may also 
increase the predictability of the market and simplify the 
logistics and the management of the stock in the pharma-
cies, especially for expensive biologics with limited shelf-
life. Thus, the optimal substitution interval for biologics 
should be determined by several factors, both theoretical 
and practical.
traceability
Traceability has been presented as a problem of biosimilar 
uptake, especially on substitution.58 In contrast to general 
perception, traceability of biosimilars and their reference 
products has been shown to be adequate.59 The main chal-
lenge in traceability of all biologics is the poor reporting of 
the batch numbers by healthcare personnel. In contrast, 
the pharmacies in Finland are already obligated to record 
the batch numbers of all dispensed biological medicines.60 
Thus, there is a good argument that traceability would be 
optimised at the pharmacy level. One issue that needs to 
be overcome, however, is that this information is not auto-
matically transferred to patient records. Nonetheless in 
Finland, it is possible for a prescriber to find the brand 
name of the dispensed medicine in the electronic archive 
of prescriptions.61 Similar helpful IT systems may be avail-
able or in development in other countries. In addition, 
traceability will be further improved in the EU by the 
recently introduced unique identifiers of all packages of 
prescribed medicinal products.62 Nevertheless, the infor-
mation flow between the healthcare units and the commu-
nity pharmacies should be improved.
Practical and policy implications
The marketing authorisation of biosimilar therapeutic 
proteins is based on the recommendation of the European 
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Medicines Agency and granted by the European Commis-
sion, whereas the interchangeability and substitutability 
are under responsibility of EU member states.63 Thus, 
each member state has to develop its own procedures 
to assess interchangeability. For example, in Finland, 
automatic substitution of generics is assessed for each 
new product entering the market.64 A separate assess-
ment of substitutability needs to be done in EU member 
states for every new biosimilar as well if substitution is 
pursued. This assessment should include the dosage 
forms, administration devices and available product 
information. Instead, in the USA, interchangeability of 
biologics is considered as an extension of the biosimilar 
status including additional clinical switching studies.65 In 
states where legislation allows, pharmacist can substitute 
products with interchangeability status.65 66 Substitution is 
allowed in some other countries, for example, in France 
and Australia.67 Despite the legal basis, clear guidance for 
substitution practice and patient counselling is needed.68
Small price difference between reference product 
and biosimilar is not encouraging physicians to switch.51 
However, substitution between the reference products 
and their biosimilars may be crucial not only for savings 
and price competition but also for practical and logistical 
reasons of limiting the number of products that must be 
stocked in the pharmacy.66
need for further research
Considering substitution in practice, it may be appro-
priate to pilot the chosen model for substitution before 
adopting the policy in full-scale. Practical, safety and 
economical aspects should be monitored and studied 
during the pilot phase in order to obtain comprehensive 
understanding of substantial benefits and risks as well as 
market dynamics associated with implementing substitu-
tion for biologics.
This study pointed out that pharmacist-provided 
patient counselling is an important factor to ensure the 
medication safety in biologics’ substitution. Despite the 
emerging biologic substitution experience in some coun-
tries, the content of the information that community 
pharmacists should provide to the patients and caregivers 
has not been studied nor reported.67–69 Especially, studies 
exploring patient perspective to biologics’ automatic 
substitution are needed.
limitations of the study
Although a wide range of stakeholders participated in 
the interviews, the community pharmacists and author-
ities constituted the majority of the participants. The 
limited number of patients and nurses compared with 
other stakeholder representatives may have skewed the 
results. This may have been partially compensated by 
the views expressed by non-patients as ‘patient percep-
tions’. However, there is often a difference between what 
patients actually think and what healthcare professionals 
believe patients to think.
The views of different professions were grouped 
together. This was because the aim of this study was to 
explore views from different stakeholders to build up a 
model for automatic substitution of biologics rather than 
to compare differences in opinions between stakeholder 
groups. We intentionally merged individual and pair/
group interviews because the stakeholders nominated a 
varying number of representatives to be interviewed. In 
each interview, the participants represented only one 
stakeholder group, which might have mitigated differ-
ences in dynamics of these approaches. The challenge 
to combine these two methods led to the decision to 
analyse the data on the level of the interviews, not by each 
interviewee.
Finally, similar to all qualitative research, it is not 
possible to fully remove researcher bias. It should be 
noted that the results reflect the local circumstances in 
Finland and may not as such be applicable to other EU 
countries. However, the majority of issues covered here 
are common to many European healthcare systems.
COnClusIOn
Perceptions of the stakeholders on automatic substitu-
tion for biologics at the pharmacy level were more posi-
tive than in previous studies. Several reservations were 
presented, and risk mitigation measures were deemed 
necessary.
The identified medication safety risks can be miti-
gated by an appropriate substitution model developed in 
collaboration with relevant stakeholders and piloted in 
pharmacies. Each biosimilar product should be assessed 
for the critical factors, such as relevant product infor-
mation (in relation to substitution), presentations and 
administration devices. The substitution also introduces 
new tasks and communication needs to those involved in 
actual medication use process, particularly to community 
pharmacists who will be responsible for substitution and 
counselling the patients. Electronic systems, such as elec-
tronic prescribing, pharmacy IT systems and unique iden-
tifiers of packages, are helpful for traceability. Consistent 
and unbiased information should be made available to 
all substitution stakeholders. The clinical and economical 
outcomes of substitution should be monitored after insti-
tution of routine substitution.
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